Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer

Ryuji Yasumatsu, Takahiro Wakasaki, Kazuki Hashimoto, Koichiro Nakashima, Tomomi Manako, masahiko taura, Mioko Matsuo, Takashi Nakagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil-to-lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab. Patients and Methods: Forty-one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment. Results: The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow-up period. Conclusion: Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.

Original languageEnglish
Pages (from-to)2610-2618
Number of pages9
JournalHead and Neck
Volume41
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Head and Neck Neoplasms
Neutrophils
Lymphocytes
Hematologic Tests
nivolumab
Treatment Failure
Survival
Therapeutics
Carcinoma, squamous cell of head and neck

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

@article{b8a29c0c311742d79ac3f2f06f9a927e,
title = "Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer",
abstract = "Background: Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil-to-lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab. Patients and Methods: Forty-one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment. Results: The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76{\%}) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91{\%}) with stable disease or partial response during the follow-up period. Conclusion: Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.",
author = "Ryuji Yasumatsu and Takahiro Wakasaki and Kazuki Hashimoto and Koichiro Nakashima and Tomomi Manako and masahiko taura and Mioko Matsuo and Takashi Nakagawa",
year = "2019",
month = "8",
day = "1",
doi = "10.1002/hed.25737",
language = "English",
volume = "41",
pages = "2610--2618",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer

AU - Yasumatsu, Ryuji

AU - Wakasaki, Takahiro

AU - Hashimoto, Kazuki

AU - Nakashima, Koichiro

AU - Manako, Tomomi

AU - taura, masahiko

AU - Matsuo, Mioko

AU - Nakagawa, Takashi

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil-to-lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab. Patients and Methods: Forty-one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment. Results: The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow-up period. Conclusion: Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.

AB - Background: Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil-to-lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab. Patients and Methods: Forty-one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment. Results: The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow-up period. Conclusion: Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85062515554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062515554&partnerID=8YFLogxK

U2 - 10.1002/hed.25737

DO - 10.1002/hed.25737

M3 - Article

AN - SCOPUS:85062515554

VL - 41

SP - 2610

EP - 2618

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 8

ER -